Not because the trials aren't there — but because no one can hold 125 active protocols and 247-page documents in working memory. Every eligible patient who isn't offered a trial is lost revenue, a lost research relationship, and a patient who may never get another option.
at a single mid-to-large research institution — far more than any one physician can track.
the cost of a 3-month enrollment slip on a single pivotal oncology study.
the typical gap since most sites genuinely reviewed a protocol they're enrolling against.
Industry-sponsored trials carry meaningful per-patient reimbursement. Every eligible patient not enrolled is recurring revenue left on the table — and enrollment delays compound it.
A missed trial isn't a missed transaction — it's a patient who may never be offered another therapeutic option. This is the access mission your institution exists to deliver.
Precision oncology is only real if biomarker results reach trial decisions. TrialPulse is the connective layer between your molecular tumor board and your open studies.
Sponsors route their best trials to sites that enroll fast and clean. Becoming that site is a durable competitive advantage — and a recruiting magnet for top oncologists.
Move the sliders to your institution's numbers. This estimates the additional trial revenue and patient matches TrialPulse could help you capture by lifting your biomarker-to-trial match rate.
Illustrative model. Assumes ~18% of oncology patients are biomarker/trial-eligible and a +22-point match-rate uplift (capped at 60%) from real-time biomarker search and cited eligibility. Replace with your actuals during a briefing.
Pressure-test these numbers with usLet us quantify the opportunity hiding in your current portfolio. We'll show you a live operating picture in 72 hours.
Tell us a little about your study and we'll tailor the demo to your protocol.